Original Research

Brief Post-Surgical Stress Management Reduces Pro-Inflammatory Cytokines in Overweight and Obese Breast Cancer Patients Undergoing Primary Treatment

Molly Ream1,*, Estefany Saez-Claire1, Chloe Taub2, Alain Diaz3, Daniela Frasca3,4, Bonnie B. Blomberg3,4, Michael H. Antoni1,5

1Department of Psychology, University of Miami, Coral Gables, FL 33146, USA
2Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
3Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL 33124, USA
4Tumor Biology Program, Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
5Cancer Control Program, Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA

*Correspondence: mxr1940@miami.edu (Molly Ream)

Academic Editor: Jordi Sastre-Serra
Submitted: 31 January 2022 Revised: 6 April 2022 Accepted: 13 April 2022 Published: 7 May 2022

Abstract

Background: Overweight and obese (OW/OB) body mass index (BMI) is associated with greater inflammation and poorer outcomes in breast cancer (BC). Stress management interventions using cognitive behavioral therapy (CBT) and relaxation training (RT) have reduced inflammation in BC patients but have not been tested specifically in OW/OB patients undergoing primary treatment. We developed brief CBT and RT-based group interventions and tested their effects (vs time-matched Health Education [HE] control) on serum inflammatory cytokines (IL-6, IL-1β and TNF-α) in OW/OB vs normal weight (NW) BC patients during primary treatment. We hypothesized OW/OB women would show higher levels of inflammatory cytokines, and that stress management would decrease these cytokines more in OW/OB women than in NW women. Methods: Stage 0–III BC patients were enrolled post-surgery and before initiating adjuvant therapy, were randomized to either 5 weeks of CBT, RT, or HE, and provided questionnaires and blood samples at baseline and 6-months. Serum cytokine levels were measured by ELISA. Repeated measures analysis of variance tested the interaction of condition by BMI by time in predicting cytokine levels over 6 months, controlling for age, stage, ethnicity, and income. Results: The sample (N = 153) majority was OW/OB (55.6%). We found differences in baseline IL-6 and IL-1β across BMI categories, with greater IL-6 (p < 0.005) and IL-1β (p < 0.04) in OW and OB vs NW women, but no difference between OW and OB women. There were no differences in baseline TNF-α among BMI groups. BMI category moderated the effect of brief stress management interventions on IL-6 changes over 6-months (p = 0.028): CBT/RT vs HE decreased IL-6 in OW/OB (p = 0.045) but not in NW patients (p = 0.664). There were no effects on IL-1β or TNF-α. Results could not be explained by differences in receipt of adjuvant therapy, prescription medications, or changes in physical activity. Conclusions: OW/OB women with newly diagnosed BC had significantly greater serum IL-6 and IL-1β than NW women post-surgery. Brief stress management delivered with primary treatment among OW/OB patients may reduce the increases in inflammatory markers known to accompany adjuvant treatments and could thus promote better outcomes. Clinical Trial Registration: NCT02103387.

Keywords: breast cancer; overweight; obese; inflammation; stress management; relaxation; cognitive behavior therapy

1. Introduction

Breast cancer (BC) is the most common cancer for women worldwide [1]. Notably, obesity has been identified as a risk factor for BC and has been associated with higher rates of obtaining a BC diagnosis and worse prognosis [2,3]. The World Health Organization (WHO) and the National Institute of Health (NIH) utilize body mass index (BMI [kg/m²]) to define the categories of overweight (OW; BMI = 25 to 29.9 kg/m²) and obese (OB; BMI ≥ 30 kg/m²). Worldwide, more than 600 million adults were classified as obese in 2015 [4]. Importantly, OW/OB individuals are at higher risk of negative health outcomes, including being at higher risk of developing cancer [5,6], including breast cancer [7–11]. Excessive weight has been associated with worse prognosis and worse mortality rates for breast cancer [3]. Additionally, both pre- and post-menopausal OW/OB women have a greater likelihood of BC recurrence and mortality [12,13]. Being overweight or obese has also been linked with an elevated risk of obtaining an additional cancer diagnosis (e.g., in the previously unaffected breast or in a separate primary site) [14,15]. Finally, chemotherapy and endocrine treatments have been reported to be less likely to be effective in women with obesity [16–20].

The relationship between obesity and BC has been attributed to chronic adipose tissue inflammation which leads to a microenvironment favorable to cancer growth [21,22]. Accordingly, obesity has been consistently linked to greater inflammation [23–28]. High adiposity in OW/OB individuals is associated with dysregulated metabolic pathways [23], including increased secretion of pro-inflammatory cy-
tokines [24–29] and adipokines [27,29]. This increased inflammation related to adipose tissue dysfunction has been linked to increased BC risk in OW/OB women [30]. Moreover, chronic inflammation and increases in pro-inflammatory cytokines tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6), which both contribute to cell proliferation in breast adipose stromal cells [23], may be a possible mechanism through which obesity contributes to worse health outcomes in diagnosed BC patients [30–32].

Despite adiposity being a theoretically modifiable factor related to inflammation, a recent meta-analysis suggests that interventions targeting adiposity (i.e., physical activity, caloric restriction, weight management) do not significantly decrease inflammatory cytokines, including IL-6 and TNF-α, in BC survivors [33]. Another modifiable factor related to inflammation is stress [34]. The stress response involves release of stress hormones including norepinephrine, epinephrine, and cortisol, as well as increased secretion of proinflammatory cytokines [34–37]. Women newly diagnosed with BC have elevated levels of depression and anxiety [38], and thus are particularly susceptible to experiencing the downstream effects of the stress response. Notably, OW/OB women with BC are more likely to have a history of chronic stress [39]. Therefore, OW/OB women with newly diagnosed BC are highly susceptible to experience increased inflammation due to chronic and acute stress, as well as increased adiposity.

Stress management interventions (e.g., Cognitive-Behavioral Stress Management [CBSM]) have reduced distress and inflammatory markers in BC patients undergoing primary treatment [40–42]. CBSM is a 10-week group-based intervention that combines relaxation training (RT) and cognitive behavioral therapy (CBT) [43]. Among women recruited in the weeks after surgery for non-metastatic BC, CBSM has been shown to reduce depressive symptoms [42], anxiety and negative affect [41] and inflammatory markers including leukocyte gene expression for IL-1β, IL-6, and TNF-α [40]. CBSM has also been associated with improved overall survival and longer disease-free survival (DFS) over an 11-year median follow-up [44]. Here greater reductions in leukocyte inflammatory gene expression with CBSM during primary treatment predicted a longer 11-year median DFS [45].

In the interest of comparing briefer forms of stress management intervention in this population we created 5-week versions of group-based CBT and RT and compared them with an attention-matched Health Education (HE) condition in women undergoing primary treatment for BC. We found both CBT and RT conditions were associated with decreases in psychological distress [46] and inflammatory markers when compared to the HE group [47,48]. However, these interventions have not been tested specifically in OW/OB women with BC. Due to the potentially interacting factors of stress and adiposity leading to increased inflammation in OW/OB women [23–28], these stress management interventions may be particularly beneficial in this vulnerable population and may lead to improved health outcomes via a reduction in inflammatory markers. Therefore, this study examined whether OW/OB women initiating treatment for BC showed higher levels of pro-inflammatory cytokines (IL-6, IL-1β and TNF-α) than normal weight (NW) women in the weeks after surgery; and whether these brief interventions reduced levels of these cytokines over a 6-month period of primary treatment to a higher degree in OW/OB women vs NW women. We hypothesized that OW/OB women would reveal greater levels of inflammatory cytokines than NW women at study entry (2–10 weeks after surgery). We also hypothesized that OW/OB women would show greater decreases (or less increases) in cytokines over the 6-month period after CBT or RT as compared to HE.

2. Materials and Methods
2.1 Participants
Participants for the current analysis were women who enrolled in a prior randomized controlled trial testing two different 5-week group-based stress management interventions, CBT and RT, vs an attention-matched HE control, which took place from 2006–2014 (National Institutes of Health Clinical Trial NCT02103387). This study was approved by the Institutional Review Board at the University of Miami. Participants completed informed consent prior to completing study procedures.

Women aged 21–75 with non-metastatic BC who were between 2- and 10-weeks post-surgery were recruited from various cancer clinics in South Florida for this trial. Exclusion criteria were clinical interview-determined severe mental illness (i.e., untreated mania or psychosis) that would interfere with ability to participate in a group intervention format, initiation of adjuvant chemotherapy or radiation treatment prior to enrollment, a previous diagnosis of cancer, and lack of English fluency.

2.2 Procedures
Enrolled participants completed a battery of psychosocial surveys and provided a blood sample at baseline (T1), prior to randomization to study condition. Women then participated in one of the three assigned group interventions (see 2.3). Immediately after the final group session, participants were given a follow-up questionnaire (T2; approximately 6 weeks post-T1) to test their perceived stress management skills. Six months post-randomization (T3), participants completed a third questionnaire to assess health behaviors and provided a second blood sample.

2.3 Intervention Conditions
All three study conditions involved 5 consecutive, weekly 1.5 hours intervention sessions in groups of 3–7 participants. Group facilitators (total = 7) were doctoral students in clinical psychology who received training to con-
duct one or more of the three group interventions, and received weekly face-to-face supervision by one of the study investigators (MHA) in order to maintain the fidelity to each intervention protocol, minimize drift and prevent contamination across study conditions. In addition to weekly sessions, all participants were also given a workbook that included the information reviewed in each session. See Supplemental Material for further information regarding intervention content.

2.3.1 Cognitive Behavioral Therapy

The CBT group condition was based on the cognitive-behavioral components of CBSM [43], which aims to teach adaptive coping within a cognitive-behavioral framework with emphasis on cancer-related stressors. Women in this condition were taught stress awareness, appraisal processes, cognitive restructuring, coping effectiveness, and interpersonal skills (i.e., assertiveness, anger management). Homework assignments were given for additional practice outside of group.

2.3.2 Relaxation Training

The RT group condition was based on the relaxation components of CBSM [43], which aimed to reduce stress and anxiety by teaching relaxation and mindfulness techniques including diaphragmatic breathing, progressive muscle relaxation, imagery, and mindful meditation. The rationale of these practices for stress management was also provided in the group format via psychoeducation. Participants were provided with audio recordings of each technique to practice at home.

2.3.3 Health Education

HE, the attention-matched control, covered educational information relevant to BC patients including symptom management, treatments and resources available, and tips for living a healthy life post-cancer diagnosis. The content of health education material was drawn from publically available sites sponsored by the American Cancer Society (ACS) and the National Cancer Institute (NCI) [49,50] and presented in PowerPoint slides in the weekly sessions. No information on stress management was provided in this control condition. This condition was included to control for facilitator attention and the presence of a supportive group similar to what is available through supportive care services at many cancer centers [51].

2.4 Measures

2.4.1 Body Mass Index

Participants self-reported height in inches and weight in pounds at T1. Given the post-hoc nature of the current analysis, the fact that the study took place in community practices, and the time elapsed since the conduct of the trial, BMI data at follow-up was not obtainable. Baseline BMI was calculated by dividing weight by height squared and multiplying by the metric conversion factor of 703 [52]. Participants were then categorized per the Center for Disease Control and Prevention as normal weight (18.5–24.9 m/kg²), overweight (25.0–29.9 m/kg²), and obese (≥30 m/kg²) [52]. No participants in our sample met criteria for the underweight category (<18.5 m/kg²) [52]. For study analyses, we combined overweight (OW) and obese (OB) individuals to maximize power, such that the two categories for BMI were normal weight (NW; 18.5–24.9 m/kg²) and overweight/obese (OW/OB; ≥25 m/kg²). However, prior to combining the OW and OB categories, we conducted descriptive analyses and three-group analysis of variance (ANOVA) of cytokine levels across all three BMI categories at T1 and T3.

2.4.2 Inflammatory Cytokines

At T1 and T3, non-fasted blood samples (35 mL) were obtained between 4:00–6:30 PM by a licensed phlebotomist and serum was subsequently separated by centrifugation. Concentration of three pro-inflammatory cytokines, IL-1β, TNF-α, and IL-6, in serum were measured using enzyme-linked immunosorbent assay (ELISA) kits from Life Technologies (Camarillo, CA, USA). All assays were conducted by trained laboratory personnel. Blood draws were conducted at baseline (T1) and 6-month follow-up (T3) only, based on prior literature demonstrating that a longer stress management intervention yielded decreased inflammatory markers at 6-months [45].

2.4.3 Perceived Stress Management Skills

The Measure of Current Status [53] was collected at T1 (baseline) and T2 (post-intervention) to measure perceived stress management skills (PSMS). We calculated a composite score of items on this measure capturing confidence in two CBT and two RT skills. This composite (α = 0.720) has been used in previous research assessing the relationship between stress management and inflammatory processes in BC patients [47]. See Supplemental Material for the questionnaire.

2.4.4 Physical Activity

Physical activity was measured with a brief version of the 7-Day Physical Activity Recall Questionnaire [54], in which patients recalled the total number of minutes of moderate and vigorous physical activity (MVPA) completed over the past 7 days. This measure has been used to capture MVPA among cancer patients [55,56]. We measured MVPA at T1 and T3. See Supplemental Material for the questionnaire.

2.4.5 Covariates

Covariates for study outcomes included age, stage of disease (0-III), household income, and ethnicity (Hispanic, non-Hispanic White, other). These variables were collected at baseline through self-report, with stage and age being...
verified with subsequent medical record review. These co-
variates were based on previous literature suggesting that
age and disease stage are related to inflammatory markers
[57], and because they have been controlled for in our past
studies relating inflammation to stress processes in breast
cancer patients undergoing primary treatment [47,58,59].
We also collected self-report data at T1 and T3 on prescrip-
tion medications [antidepressants, anxiolytics (drugs reliev-
ing anxiety), pain medications, sleep medications], and ad-
juvant treatments received (chemotherapy/radiation) in the
period leading up to T3. We also collected self-reported
data at T1 on presence of medical comorbidities, includ-
ing diabetes, myocardial infarction, peripheral vascular dis-
ease, and connective tissue disease.

2.5 Analytic Plan
All analyses were conducted using the Statistical
Package for the Social Sciences (SPSS) Version 27 (IBM
Corp. Armonk, NY, USA) [60]. Data were initially
screened for skewness and kurtosis. Values of IL-6, IL-
1β, and TNF-α were skewed at T1 and T3. As such, all
cytokine values were log-transformed, achieving normal-
ity. Raw cytokine values (pg/mL) are reported in tables for
interpretability.

First, to justify collapsing overweight and obese BMI
groupings to the OW/OB category and collapsing the two
active stress management conditions (CBT/RT), we con-
ducted two three-group analysis of variance (ANOVA)
tests: (1) between CBT, RT, and HE, and (2) between NW,
OW, and OB weight groupings, each predicting both T1 and
T3 cytokine levels.

After we justified collapsing these categories, prelimi-
ary analyses were conducted to determine whether inter-
vention condition or BMI predicted inflammation or vari-
ables potentially related to inflammation at T1 and T3. We
compared active (CBT/RT) vs control (HE) groups separ-
ately by BMI category for baseline cytokine levels, self-
reported physical activity (MVPA) levels, income, age,
days from surgery to baseline assessment, and group at-
tendance using t-tests. Chi-square tests were also used
to examine differences between study conditions by BMI
category on categorical variables at T1 and T3 including
ethnicity (T1 only), prescription medications (antidepress-
sants, anxiolytics, pain medications, sleep medications),
chemotherapy/radiation receipt, stage of disease, ER/PR
status, type of surgery (mastectomy vs lumpectomy), and
receipt of reconstructive surgery.

Third, we conducted a manipulation check to deter-
mine whether women receiving CBT/RT had improved
stress management skills over the course of the interven-
tion as compared to the HE control. To test whether in-
tervention condition affected perceived stress management
skills pre- to post-intervention, and whether this differed
by BMI, we tested a two condition (CBT/RT vs HE) by
two group (OW/OB vs NW) by two timepoint (T1, T2)
repeated measures ANOVA (RMANOVA) on the PSMS
composite score, controlling for previously stated covari-
ates. RMANOVA uses listwise deletion for missing data.

To test our primary hypothesis that baseline BMI
moderated the effect of intervention condition (CBT/RT
vs HE) on inflammatory cytokines pre- to 6-months post-
randomization, we tested a two condition (CBT/RT vs HE)
by two group (OW/OB vs NW) by two timepoint (T1, T3)
RMANOVA on each inflammatory cytokine (IL-6, IL-1β,
and TNF-α). In the case of a significant three-way in-
teraction, we investigated the simple two-way interactions of
condition by time at the different levels of BMI.

Finally, to investigate one potential mechanism
by which the interventions may decrease inflammation,
we assessed whether the relationship between condition
(CBT/RT vs HE) and the change in self-reported weekly
hours of MVPA from T1 to T3 was moderated by BMI. To
assess this, we tested a two condition (CBT/RT vs HE)
by two group (OW/OB vs NW) by two timepoint (T1, T3)
RMANOVA on MVPA weekly hours. We then tested
whether the moderating effect of BMI on intervention ef-
fects on cytokine changes held after controlling for contem-
poraneous changes in MVPA. The two-tailed alpha level for
all analyses was set at 0.05.

3. Results
In total, 739 women were assessed for eligibility, of
which 194 met eligibility criteria and signed consent. Of
these, 184 completed baseline procedures and were ran-
donized. For the present analysis, we looked at the subsam-
ple of participants who self-reported weight and height data
at baseline (N = 153; 83.2%). Women who declined to pro-
vide height and weight data did not differ from those who
did on baseline levels of IL-6 (t(175) = –0.68, p = 0.498),
IL-1β (t(176) = –0.65, p = 0.515), or TNF-α (t(176) = –
0.27, p = 0.789), but were on average younger (t(180) =
–2.31, p = 0.022) and had a lower income (t(180) = –2.45,
p = 0.015). All 153 women completed baseline psychoso-
erial questionnaires and 149 women provided blood samples
at baseline. Post-intervention, 121 women completed the
T2 perceived stress management skill measure (PSMS),
and 103 gave a second blood sample at T3. See Fig. 1 for the
CONSORT diagram.

3.1 Participant Characteristics
The sample (N = 153) was predominately middle-
aged (M = 55.07, SD = 10.02), White (43.3%) and His-
panic (42.0%), with stage 1 (55.6%) disease. The majority
(55.6%) fell within the OW/OB BMI (OW = 27.5%, OB =
28.1%), and 44.4% fell within the NW range. See Table 1
for full demographics and study variables by BMI classifi-
cation and Table 2 for demographics and study variables by
intervention condition.
3.2 Preliminary Analyses

We first compared cytokine values at baseline between intervention conditions (CBT, RT, HE) and between BMI groups (NW, OW, OB) using ANOVA. At baseline, there was a significant difference between intervention conditions in IL-1β (F(2,146) = 3.21, p = 0.043); however, post-hoc Fisher Least Squared Differences (LSD) tests showed only a marginally significant difference between RT and HE at baseline (p = 0.074) and no condition differences in baseline IL-6 (F(2,145) = 0.73, p = 0.484) or TNF-α (F(2,146) = 0.39, p = 0.681).

As hypothesized there was a significant overall difference in baseline IL-6 (F(2,145) = 8.45, p < 0.001) and IL-1β (F(2,146) = 3.89, p = 0.023) across BMI categories. Post-hoc LSD pairwise tests showed significantly greater IL-6 in OW (p = 0.005) and OB (p < 0.001) women vs NW women, but no statistical difference between OW and OB women (p = 0.400). Similar results were observed for baseline IL-1β (NW vs OW, p = 0.014; NW vs OB, p = 0.037; OB vs OW, p = 0.704). There were no baseline differences in TNF-α values among BMI groups. See Fig. 2 for baseline means of each cytokine level across the three BMI categories. Given these results and to optimize power, BMI categories for overweight and obese (OW/OB) were combined as were the two active stress management intervention conditions (CBT/RT) for all subsequent analyses.

Only one participant (CBT/RT; OW/OB) received chemotherapy within the 3 weeks prior to T3, and only one participant (HE; OW/OB) received chemotherapy within the 3 weeks prior to T3. Neither receipt of chemotherapy (F(1,105) = 0.028, p = 0.868) nor radiation (F(1,105) = 0.754, p = 0.387) significantly predicted the change in IL-6. Similar results were observed for predicting change in IL-1β (chemotherapy receipt: (F(1,109) = 0.003, p = 0.959); radiation receipt: F(1,109) = 0.448, p = 0.505). Radiation receipt did significantly predict the change in TNF-α over time (F(1,109) = 8.82, p = 0.004), but chemotherapy receipt did not (F(1,109) = 1.02, p = 0.315). There were no differences in prescription medications (anxiolytics, antidepressants, sleep medications, or pain medications), ER/PR status, receipt of reconstructive surgery before T3, or surgery type (mastectomy vs lumpectomy) by BMI (Table 1) or intervention arm (Table 2). Self-reported comorbidities showed no differences between OB/OV vs NW women (p > 0.05) with the exception of diabetes, which showed greater prevalence in women classified as OW/OB (n = 11, 13.4%) compared to NW (n = 2, 2.9%) χ²(1) = 5.15, p = 0.023).

Most participants (61.4%) completed at least 4 out of 5 intervention sessions. There was no significant difference in session attendance between BMI categories (p = 0.085), with NW women attending an average of 4.29 out of 5 sessions as compared to OW/OB women attending an average 3.86 out of 5 sessions. A two condition (CBT/RT vs HE) by two group (OW/OB vs NW) by two timepoint (T1, T2) RMANOVA predicting the PSMS composite score was
Table 1. Demographic and study variables by BMI category.

|                      | NW          | OW/OB       | Statistic | Diff  |
|----------------------|-------------|-------------|-----------|-------|
|                      | (N = 66)    | (N = 83)    |           |       |
| **Baseline (T1)**    |             |             |           |       |
| IL-6 (ln)            | 0.33 (1.34) | 1.24 (1.40) | *t*(146) = –4.03 | *p < 0.001*** |
| IL-6 (ng/mL)         | 3.79 (8.73) | 15.29 (69.55) | –        | –     |
| IL-1β (ln)           | –0.60 (1.90) | 0.26 (1.90) | *t*(147) = –2.76 | *p = 0.007** |
| IL-1β (ng/mL)        | 3.58 (10.68) | 7.90 (22.77) | –        | –     |
| TNF-α (ln)           | 0.41 (0.10) | 0.43 (1.12) | *t*(147) = –0.13 | *p = 0.893 |
| TNF-α (ng/mL)        | 2.34 (2.33) | 3.84 (13.05) | –        | –     |
| Anti-dep.            | 5 (7.3%)    | 11 (13.6%)  | *χ²(1) = 3.14 | *p = 0.221 |
| Anxiolytic           | 10 (14.7%)  | 14 (17.3%)  | *χ²(1) = 0.16 | *p = 0.694 |
| Pain med             | 12 (17.6%)  | 14 (17.3%)  | *χ²(1) = 0.01 | *p = 0.954 |
| Sleep med            | 12 (17.6%)  | 12 (14.6%)  | *χ²(1) = 0.25 | *p = 0.616 |
| MVPA (hours)         | 1.30 (1.94) | 0.76 (1.64) | *t*(132) = 1.75 | *p = 0.082* |
| Age                  | 53.85 (10.6) | 54.71 (10.3) | *t*(108) = –0.42 | *p = 0.676 |
| Income               | 110.5 (69.7) | 118.65 (79.2) | *t*(108) = –0.56 | *p = 0.573 |
| Stage                |            |             |           |       |
| Stage 0              | 13 (19.1%)  | 13 (15.3%)  | *χ²(3) = 4.85 | *p = 0.183 |
| Stage 1              | 41 (60.3%)  | 44 (51.8%)  | –        | –     |
| Stage 2              | 10 (14.7%)  | 25 (29.4%)  | –        | –     |
| Stage 3              | 4 (5.9%)    | 3 (3.5%)    | –        | –     |
| ER+ Status           | 55 (84.6%)  | 71 (87.7%)  | *χ²(1) = 0.28 | *p = 0.596 |
| PR+ Status           | 48 (73.8%)  | 62 (79.5%)  | *χ²(1) = 0.64 | *p = 0.425 |
| Mastectomy           | 34 (50.0%)  | 43 (50.6%)  | *χ²(1) = 0.01 | *p = 0.942 |
| Time f/ surg.        | 37.3 (25.2) | 35.7 (20.2) | *t*(151) = 0.44 | *p = 0.661 |
| Ethnicity            |            |             |           |       |
| NHW                  | 37 (60.7%)  | 28 (35.4%)  | *χ²(2) = 8.91 | *p = 0.021* |
| Hispanic             | 21 (34.4%)  | 43 (54.4%)  | –        | –     |
| Other                | 3 (4.9%)    | 8 (10.1%)   | –        | –     |
| **Follow-up (T3)**   |             |             |           |       |
| IL-6 (ln)            | 0.75 (1.44) | 1.35 (1.25) | *t*(99) = –2.25 | *p = 0.027* |
| IL-6 (ng/mL)         | 7.49 (19.48) | 10.27 (21.51) | –        | –     |
| IL-1β (ln)           | 0.04 (2.14) | 0.43 (2.16) | *t*(101) = –0.92 | *p = 0.360 |
| IL-1β (ng/mL)        | 7.55 (19.12) | 11.45 (36.36) | –        | –     |
| TNF-α (ln)           | 0.38 (1.62) | 0.43 (1.50) | *t*(101) = –0.14 | *p = 0.893 |
| TNF-α (ng/mL)        | 3.57 (4.03) | 3.45 (4.10) | –        | –     |
| Anti-dep.            | 5 (8.9%)    | 4 (6.7%)    | *χ²(1) = 0.21 | *p = 0.649 |
| Anxiolytic           | 12 (21.4%)  | 6 (9.8%)    | *χ²(1) = 3.01 | *p = 0.083* |
| Pain med             | 10 (17.9%)  | 3 (5.0%)    | *χ²(1) = 4.81 | *p = 0.028* |
| Sleep med            | 11 (20.0%)  | 9 (15.0%)   | *χ²(1) = 0.50 | *p = 0.480 |
| Radiation            | 9 (16.1%)   | 11 (18.3%)  | *χ²(1) = 0.11 | *p = 0.746 |
| Chemo                | 5 (8.9%)    | 4 (6.7%)    | *χ²(1) = 0.21 | *p = 0.651 |
| Reconstr.            | 14 (24.6%)  | 22 (36.1%)  | *χ²(1) = 1.84 | *p = 0.175 |
| MVPA (hours)         | 0.67 (0.73) | 0.57 (0.73) | *t*(103) = 0.63 | *p = 0.533 |
| Attendance           | 4.29 (1.17) | 3.86 (1.49) | *t*(120) = 1.74 | *p = 0.085* |

Sample size based on participants with cytokine data. CBT, Cognitive Behavioral Therapy; RT, Relaxation Training; HE, Health Education; Anti-dep., antidepressant; MVPA, weekly moderate/vigorous physical activity; med, medicine; NHW, non-Hispanic White; chemo, chemotherapy; time f/ surg., days from surgery until T1; reconst, reconstructive surgery. Income measured in thousands. $^p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001.$
Table 2. Demographic and study variables by study condition within BMI category.

|                  | Baseline (T1)   | CBT/RT (N=42) | HE (N=24) | Statistic | Diff. | Follow-up (T3)   | CBT/RT (N=33) | HE (N=21) | Statistic | Diff. |
|------------------|-----------------|---------------|-----------|-----------|-------|------------------|---------------|-----------|-----------|-------|
| **IL-6 (ng/mL)** | 0.29 (1.25)     | 0.39 (1.50)   | -         | t(64) = -0.26 | p = 0.792 |
|                  | 2.75 (4.12)     | 5.62 (13.40)  | -         | -         |       | 1.83 (8.30)     | 8.77 (21.65)  | -         | -         |       |
| **IL-1β (ng/L)** | -0.33 (1.78)    | 1.08 (2.04)   | t(64) = 1.56 | p = 0.124 |
|                  | 3.00 (5.59)     | 4.58 (16.27)  | -         | -         |       | 8.53 (25.00)    | 6.00 (17.71)  | -         | -         |       |
| TNF-α (ng/mL)    | 0.57 (1.04)     | 0.12 (0.86)   | t(64) = 1.79 | p = 0.074* |
|                  | 2.75 (2.59)     | 1.63 (1.59)   | -         | -         |       | 4.00 (15.68)    | 3.51 (4.08)   | -         | -         |       |
| Anti-dep.        | 11.16%          | 0%            | χ²(1) = 3.14 | p = 0.150 |
| Pains             | 20.9%           | 312.0%        | χ²(1) = 0.87 | p = 0.352 |
| Sleep             | 716.3%          | 520%          | χ²(1) = 0.15 | p = 0.700 |
| MVPA (hours)     | 1.40 (1.32)     | 1.83 (2.14)   | t(58) = 0.53 | p = 0.597 |
| Age              | 52.88 (10.6)    | 55.52 (10.5)  | t(66) = -0.99 | p = 0.326 |
| Ethnicity         | 94.84 (50.8)    | 137.43 (88.8) | t(66) = -2.53 | p = 0.014* |
| ER+ Status       | 11 (25.6%)      | 2 (8.0%)      | 7 (12.1%) | 6 (22.2%) |
| PR+ Status       | 24 (55.8%)      | 17 (68.0%)    | 32 (55.2%) | 12 (44.4%) |
| Mastectomy       | 6 (14.0%)       | 4 (16.0%)     | 17 (29.3%) | 8 (29.6%) |
| Time f/ surg.    | 39.2 (29.6)     | 34.0 (15.0)   | t(66) = 0.81 | p = 0.419 |
| Ethnicity         | 21 (56.8%)      | 16 (66.7%)    | 19 (35.8%) | 9 (34.6%) |
| Hispanic          | 15 (40.5%)      | 6 (25.5%)     | 29 (54.7%) | 14 (53.8%) |
| Other            | 1 (2.7%)        | 2 (8.3%)      | 5 (9.4%)  | 3 (11.5%) |

Sample size based on participants with cytokine data. CBT, Cognitive Behavioral Therapy; RT, Relaxation Training; HE, Health Education; Anti-dep., antidepressant; MVPA, weekly hours of moderate/vigorous physical activity; med, medicine; NHW, non-Hispanic White; chemo, chemotherapy; time f/ surg., days from surgery until T1; reconstr, reconstructive surgery. Income measured in thousands. *p < 0.10, **p < 0.05, ***p < 0.01.
Fig. 2. Mean baseline cytokine values by BMI category in breast cancer patients 2–10 weeks post-surgery and prior to initiating adjuvant chemotherapy or radiation. Cytokine levels are log-transformed to achieve normality. Error bars represent 95% confidence intervals. There was a significant overall difference in baseline IL-6 (F(2,145) = 8.45, \( p < 0.001 \)), shown in Fig. 2A and IL-1\( \beta \) (F(2,146) = 3.89, \( p = 0.023 \)), shown in Fig. 2B across BMI categories. There was significantly greater IL-6 in overweight (\( p = 0.005 \)) and obese (\( p < 0.001 \)) women vs normal weight women, but no statistical difference between overweight and obese women (\( p = 0.400 \)). Similar results were observed for baseline IL-1\( \beta \) (normal weight vs overweight, \( p = 0.014 \); normal weight vs obese, \( p = 0.037 \); obese vs overweight, \( p = 0.704 \)). There were no baseline differences in TNF-\( \alpha \) values among BMI groups, shown in Fig. 2C.

run as a manipulation check. There was a significant time by condition interaction (F(1,102) = 9.52, \( p = 0.003 \)), such that women in the active CBT/RT conditions had greater increases in perceived stress management skills over time compared to women in the HE control condition. The three-way interaction was not significant (F(1,102) = 3.16, \( p = 0.078 \)). Thus, assignment to either of the stress management interventions produced greater improvements in perceived stress management skills as compared to the HE condition irrespective of BMI group.

3.3 Main Analyses of Intervention Effects

A two condition (CBT/RT vs HE) by two group (OW/OB vs NW) by two timepoint (T1, T3) RMANOVA predicting IL-6 was run. There was no main effect of time in predicting IL-6 (F(1,86) = 0.44, \( p = 0.410 \)), but there was a main effect of BMI (F(1,86) = 9.66, \( p = 0.003 \)), with OW/OB women having greater IL-6 levels across timepoints and conditions. There was a significant three-way time by BMI by condition interaction (F(1,86) = 5.00, \( p = 0.028 \)), indicating moderation. Given the significant three-way interaction, we conducted subgroup analyses by BMI. There was no significant time by condition interaction among NW women, F(1,37) = 0.19, \( p = 0.664 \), but there was a time by condition interaction among OW/OB women (F(1,45) = 4.24, \( p = 0.045 \)), such that only OW/OB women experienced decreased IL-6 over time when receiving CBT/RT vs HE, as shown by the the mean change score in IL-6 by study condition (CBT/RT vs HE) among OW/OB women (Fig. 3). Supplementary Fig. 1 shows IL-6 change scores by intervention in OW and OB women separately for descriptive purposes. In each case assignment to CBT/RT was associated with a decrease or no increase in IL-6 vs a rise in IL-6 in HE.

Fig. 3. Change in IL-6 pre- to 6-months post-intervention by study condition (CBT/RT vs HE) among overweight and obese women with breast cancer combined. Cytokine levels are log-transformed to achieve normality. Error bars represent 95% confidence intervals. RMANOVA indicated that overweight/obese women receiving CBT/RT had significantly decreased IL-6 levels over time vs those who received HE (F(1,45) = 4.24, \( p = 0.045 \)).

An additional two condition (CBT/RT vs HE) by two group (OW/OB vs NW) by two timepoint (T1, T3) RMANOVA predicting IL-1\( \beta \) was run. There was no main effect of time (F(1,89) = 0.04, \( p = 0.845 \)) or of BMI (F(1,89)
We did not find any evidence of a relationship between 5-week stress management, BMI, and the change in inflammatory IL-1/β or TNF-α over the study period. This contrasts with previous findings that a 10-week cognitive behavioral stress management group intervention was associated with reductions in leukocyte TNFα gene expression [40]. It is possible that there is a dose-dependent response of stress management, such that a briefer intervention, while potentially more feasible during primary care, is less potent.

A manipulation check demonstrated that women who received the active stress management conditions reported significantly increased perceived stress management skills vs those in the HE control condition, which verified that our active conditions were effectively training participants. Notably, this effect did not differ by BMI. Thus, although both OW/OB and NW women receiving stress management interventions reported significantly greater confidence in their ability to manage stress, unique processes occurred within OW/OB women resulting in decreased IL-6 levels over the study period. It is likely that OW/OB women, who presented with significantly higher IL-6 at baseline, were more able to benefit physiologically from a stress management intervention due to the co-occurring, and potentially interacting, effects of acute stress [38], chronic stress [39], and adiposity [24–29] on neuroendocrine regulation and inflammation. Providing coping and relaxation techniques may have been more impactful in this particularly vulnerable population.

Our analyses were unable to identify the mechanism by which these interventions affected biomarkers within OW/OB women. Given that physical activity is related to inflammatory markers [65] and BMI (i.e., increases in physical activity may reduce BMI), and prior evidence that stress management interventions in other trials may increase engagement in physical activity during BC treatment [66], we tested whether there was an increase in MVPA among OW/OB women participating in stress management groups. However, there was no significant intervention condition by BMI by time interaction effect on MVPA over the study period. Overall, MVPA decreased over the study period across all conditions and BMI categories, likely due to physical limitations associated with adjuvant treatment, and was not a likely explanation for the effects of stress management intervention on cytokine changes. Since there were no differences in adjuvant treatments or other medications received among conditions, we can rule out these as contributing to our results.

Future research should continue to investigate potential mechanisms of change that may explain the relationship between BMI, stress management, and inflammation in BC patients. For example, it is possible stress management may decrease negative self-view and internalized weight stigma among OW/OB women, thereby decreasing stress and inflammation. There is literature suggesting that OW/OB individuals experience significant weight stigma and dis-
crimination in the United States [67–69]. Some OW/OB individuals internalize this weight stigma, thus devaluing themselves based on their weight [70]. Stress management interventions may influence internalized weight stigma by targeting and reappraising cognitions and can provide adaptive coping mechanisms for the related distress. These skills may also allow them to better cope with external weight stigma they face, which have been shown occur frequently in healthcare settings [69], as these women navigate frequent medical appointments for their BC treatment.

In addition, it is possible women who received stress management replaced maladaptive coping techniques with adaptive coping skills. For example, women in stress management conditions may engage in cognitive restructuring (in CBT condition) or mindfulness meditation (in RT condition) when distressed as opposed to emotional eating, a common stress response that may lead to further distress [71] and which may contribute to the development and maintenance of obesity [72]. There is evidence that both behavioral [73] and mindfulness-based psychological interventions [74] decrease emotional eating behaviors. Therefore, it is plausible that in our sample, OW/OB women in the stress management conditions decreased maladaptive emotional eating and increased adaptive coping responses, thereby increasing psychological well-being, and decreasing circulating inflammatory cytokines. Future research should investigate the role of emotional eating in the relationship between BMI, stress management, and inflammation, as well as the role of other eating styles (i.e., mindful vs mindful eating [75], intuitive eating [76], restrictive eating [77]), to add further nuance to these findings.

There are several limitations of the current study to note. First, BMI was calculated through self-report by participants, which may be subject to error. However, there is data demonstrating that self-report and objective weights are generally well-correlated [78,79]. In addition, 30 women who participated in the original trial (16.3%) declined to provide height and weight data and were thus excluded from the current analysis, which may add selection bias to our findings. Further, BMI as a measure of weight status has limitations and may lack specificity in estimating body fat. Due to the nature of the post-hoc analyses, we did not have a longitudinal measure of BMI or weight at follow-up, and therefore cannot know if the change in inflammatory cytokines in the OW/OB women receiving stress management is related to a decrease in weight over the study period. In addition, we did not have a standardized measure of diet or eating styles pre- to post-intervention, which would have added greater nuance to our findings. However, intervention effects on IL-6 held when controlling for contemporaneous changes in physical activity, providing some evidence that our results were not due to changes in energy balance over the study period.

The current analysis is also limited in that adipokines were not collected in addition to cytokines. The relationship between obesity and BC is thought to be likely related to both inflammation, measured here by inflammatory cytokines, as well as deregulation of adipokine secretion [80]. Adiponectin is the most numerous adipokine, has anti-inflammatory properties, and may decrease tumor proliferation, but is significantly decreased in OW/OB women [80–83]. In addition, we did not collect data on the expression of genes that are associated with inflammation and health outcomes in BC, including ErbB2 [84]. Future research should determine whether stress management impacts adiponectin in OW/OB women, and whether specific gene expression may play a role in the relationship between stress and inflammation in OW/OB women with BC.

Despite these limitations, the current study has several strengths. We analyzed immunological, psychological, and behavioral data from a diverse cohort of women (42% Hispanic) with newly diagnosed BC who had participated in a prior RCT. This study adds to the current literature by examining how brief stress management interventions comprising CBSM (CBT- and RT-based) may impact inflammatory biomarkers among BC patients with different BMI levels. This work has important implications for further understanding the biobehavioral mechanisms by which OW/OB women with BC experience worse health outcomes [85,86], and to work towards developing targeted interventions to improve outcomes among this high-risk population.

5. Conclusions

OW and OB women with newly diagnosed BC had significantly greater levels of IL-6 and IL-1β, which are known to promote poorer health outcomes, as compared to NW women in the post-surgical period. This identifies OW/OB BC patients as a vulnerable group deserving more attention in future research. BMI category also influenced the effect of brief stress management interventions on changes in levels of IL-6, such that stress management (vs a health education control) significantly decreased IL-6 in OW/OB but not NW individuals. Future work should conduct large-scale trials of brief accessible stress management interventions such as these in OW/OB women with BC early in primary treatment and explore the mechanisms by which stress management reduces inflammation and improves future health outcomes in this understudied population.

Abbreviations

ACS, American Cancer Society; ANOVA, Analysis of variance; BC, Breast cancer; BMI, Body mass index; CBSM, Cognitive-Behavioral Stress Management; CBT, Cognitive behavioral therapy; CDC, Center for Disease Control and Prevention; DFS, Disease-free survival; ELISA, Enzyme-linked immunosorbent assay; ER/PR, Estrogen receptor/Progesterone receptor; HE, Health education; IL-1β, Interleukin-1 beta; IL-6, Interleukin-6; LSD, Least Squared Differences; MVPA, Moderate and vigorous
physical activity; NCI, National Cancer Institute; NHW, Non-Hispanic White; NIH, National Institutes of Health; NW, Normal weight; OW/OB, Overweight and obese; PSMS, Perceived stress management skills; RMANOVA, Repeated Measures Analysis of variance; RT, Relaxation training; SD, Standard deviation; SPSS, Statistical Package for the Social Sciences; T1, Timepoint 1: Baseline timepoint; T2, Timepoint 2: ~6-weeks post baseline; T3, Timepoint 3: Six months after randomization; TNF-α, Tumor necrosis factor alpha; WHO, World Health Organization.

Author Contributions
MR, MA and BB conceptualized the current study. AD performed the research. MR analyzed the data. MA, BB, AD, CT, and DF provided guidance on analyses and interpretation. MR, ESC, and MA wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate
This trial was approved by the Institutional Review Board at the University of Miami and is registered as National Institutes of Health Clinical Trial NCT02103387. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. All women participating in the study completed informed consent procedures.

Acknowledgment
Not applicable.

Funding
This work was supported by the National Cancer Institute (2R01CA064710-10A1).

Conflict of Interest
Michael Antoni reports that he is a paid consultant for Blue Note Therapeutics and Atlantis Healthcare, two digital health companies, is the inventor of CBSM (UMIP-483), and receives royalties for published CBSM treatment manuals. Chloe Taub is also a paid consultant for Blue Note Therapeutics. None of the other authors have conflicts of interest to report. DF is serving as the editorial board member of this journal. We declare that DF had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to GP.

Supplementary Material
Supplementary material associated with this article can be found, in the online version, at https://doi.org/10.31083/j.fbl2705148.

References
[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA - A Cancer Journal for Clinicians. 2021; 71: 209–249.
[2] Heetun A, Curess RI, Copson ER. Early breast cancer: why does obesity affect prognosis? Proceedings of the Nutrition Society. 2018; 77: 369–381.
[3] Barone I, Caruso A, Gelsomino L, Giordano C, Bonofiglio D, Catalano S, et al. Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives. Obesity Reviews. 2021; 23: e13358.
[4] Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine. 2017; 377: 13–27.
[5] Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. The Lancet. 2008; 371: 569–578.
[6] Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. The Lancet. 2014; 384: 755–765.
[7] Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis. International Journal of Cancer. 2009; 124: 698–712.
[8] Vrieling A, Buck K, Kaaks R, Chang-Claude J. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Research and Treatment. 2010; 123: 641–649.
[9] Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body Mass Index and Breast Cancer Risk According to Postmenopausal Estrogen-Progestin Use and Hormone Receptor Status. Epidemiologic Reviews. 2014; 36: 114–136.
[10] Neuhauser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk. JAMA Oncology. 2015; 1: 611–621.
[11] Nattenmüller CJ, Kriegsmann M, Sookthai D, Fortner RT, Stefan A, Walter B, et al. Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study. BMC Cancer. 2018; 18: 616.
[12] Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Research and Treatment. 2010; 123: 627–635.
[13] Chan DSM, Vieira AR, Aune D, Bander EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies. Annals of Oncology. 2014; 25: 1901–1914.
[14] Majed B, Doozal A, Ribassin-Majed L, Senouci K, Asselain B. Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association. Breast Cancer Research and Treatment. 2011; 126: 729–738.
[15] Druesne-Pecollo N, Touvier M, Barrandon E, Chan DSM, Norat T, Zelak I, et al. Excess body weight and secondary primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies. Breast Cancer Research and Treatment. 2012; 135: 647–654.
[16] Griggs JJ, Sorbero MES, Lyman GH. Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy. Archives of Internal Medicine. 2005; 165: 1267–1273.
[17] Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. The Lancet. 2005; 366: 1108–1110.
Argolo DF, Hudis CA, Iyengar NM. The Impact of Obesity on Breast Cancer. Current Oncology Reports. 2018; 20: 47.

Vayssé C, Muller C, Fallone F. Obesity: a heavy-weight player in breast cancer’s chemoresistance. Oncotarget. 2019; 10: 3207–3208.

Ewertz M, Jensen M, Gunnarsdóttir K, Hojris I, Jakobsen EH, Nielsen D, et al. Effect of Obesity on Prognosis after Early-Stage Breast Cancer. Journal of Clinical Oncology. 2011; 29: 25–31.

Kolb R, Zhang W. Obesity and Breast Cancer: A Case of Inflamed Adipose Tissue. Cancers. 2020; 12: 1686.

Bhardwaj P, Brown KA. Obese Adipose Tissue as a Driver of Breast Cancer Growth and Development: Update and Emerging Evidence. Frontiers in Oncology. 2021; 11: 638918.

Brown KA. Metabolic pathways in obesity-related breast cancer. Nature Reviews Endocrinology. 2021; 17: 350–363.

Boutens I, Stienstra R. Adipose tissue macrophages: going off track during obesity. Diabetologia. 2016; 59: 879–894.

Zhao C, Hu W, Xu Y, Wang D, Wang Y, Lv W, et al. Current Landscape: The Mechanism and Therapeutic Impact of Obesity for Breast Cancer. Frontiers in Oncology. 2021; 11: 704893.

Frasca D, Ferracci F, Díaz A, Romero M, Lechner S, Blomberg BB. Obesity decreases B cell responses in young and elderly individuals. Obesity. 2016; 24: 615–625.

Díaz A, Romero M, Vazquez T, Lechner S, Blomberg BB, Frasca D. Metformin improves in vivo and in vitro B cell function in individuals with obesity and Type-2 Diabetes. Vaccine. 2017; 35: 2694–2700.

Frasca D, Blomberg BB. Adipose tissue, immune aging and cellular senescence. Seminars in Immunopathology. 2020; 42: 573–587.

Holm JB, Rosendahl AH, Borgquist S. Local biomarkers involved in the interplay between obesity and breast cancer. Cancers. 2021; 13: 6286.

Kulkarni A, Bowers LW. The role of immune dysfunction in obesity-associated cancer risk, progression, and metastasis. Cellular and Molecular Life Sciences. 2021; 78: 3423–3442.

Jung SY, Scott PA, Papp JC, Sobel EM, Pellegrini M, Yu H, et al. Genome-wide Association Analysis of Proinflammatory Cytokines and Gene–lifestyle Interaction for Invasive Breast Cancer Risk: the WHI dbGaP Study. Cancer Prevention Research. 2021; 14: 41–54.

Inglis JE, Kleckner AS, Lin P, Gilmore NJ, Culakova E, Vander-Woude AC, et al. Excess Body Weight and Cancer-Related Fatigue, Systemic Inflammation, and Serum Lipids in Breast Cancer Survivors. Nutrition and Cancer. 2021; 73: 1676–1686.

Bruinsma TJ, Dyer A, Rogers CJ, Schmitz KH, Sturgeon KM. Effects of Diet and Exercise-Induced Weight Loss on Biomarkers of Inflammation in Breast Cancer Survivors: a Systematic Review and Meta-analysis. Cancer Epidemiology, Biomarkers & Prevention. 2021; 30: 1048–1062.

Antoni MH, Dhabhar FS. The impact of psychosocial stress and stress management on immune responses in patients with cancer. Cancer. 2019; 125: 1417–1431.

Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain, Behavior, and Immunity. 2007; 21: 901–912.

Aschbacher K, Eipel E, Wolkowitz OM, Prather AA, Puterman E, Dhabhar FS. Maintenance of a positive outlook during acute stress protects against pro-inflammatory reactivity and future depressive symptoms. Brain, Behavior, and Immunity. 2012; 26: 346–352.

Puterman E, Eipel ES, O’Donovan A, Prather AA, Aschbacher K, Dhabhar FS. Anger is Associated with Increased IL-6 Stress Reactivity in Women, but only among those Low in Social Support. International Journal of Behavioral Medicine. 2014; 21: 936–945.

Carreira H, Williams R, Müller M, Harewood R, Stanway S, Bhaskaran K. Associations between Breast Cancer Survival and Adverse Mental Health Outcomes: a Systematic Review. Journal of the National Cancer Institute. 2018; 110: 1311–1327.

Cormuànicque TF, Almeida LEDFD, Rech CA, Rech D, Herrera ACDSDA, Panis C. Chronic psychological stress and its impact on the development of aggressive breast cancer. Einstein. 2015; 13: 352–356.

Antoni MH, Rutgersen SK, Blomberg B, Carver CS, Lechner S, Díaz A, et al. Cognitive Behavioral Stress Management Reverses Anxiety-Related Leukocyte Transcriptional Dynamics. Biological Psychiatry. 2012: 71: 366–372.

Antoni MH, Wimberly SR, Lechner SC, Kazi A, Sifre T, Urcuyo KR, et al. Reduction of Cancer-Specific Thought Intrusions and Anxiety Symptoms with a Stress Management Intervention among Women Undergoing Treatment for Breast Cancer. American Journal of Psychiatry. 2006; 163: 1791–1797.

Antoni MH, Lehman JM, Kilbourn KM, Boyers AE, Culver JL, Alferi SM, et al. Cognitive-behavioral stress management intervention decreases the prevalence of depression and enhances benefit finding among women under treatment for early-stage breast cancer. Health Psychology. 2001; 20: 20–32.

Antoni MH. Stress management intervention for women with breast cancer. American Psychological Association: Washington, DC. 2003.

Stagl JM, Lechner SC, Carver CS, Bouchard LC, Gudenkauf LM, Jutagir DR, et al. A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up. Breast Cancer Research and Treatment. 2015; 154: 319–328.

Antoni MH, Bouchard LC, Jacobs JM, Lechner SC, Jutagir DR, Gudenkauf LM, et al. Stress management, leukocyte transcriptional changes and breast cancer recurrence in a randomized trial: an exploratory analysis. Psychoneuroendocrinology. 2016; 74: 269–277.

Gudenkauf LM, Antoni MH, Stagl JM, Lechner SC, Jutagir DR, Bouchard LC, et al. Brief cognitive-behavioral and relaxation training interventions for breast cancer: a randomized controlled trial. Journal of Consulting and Clinical Psychology. 2015; 83: 677–688.

Taub CJ, Lippman ME, Hudson BI, Blomberg BB, Díaz A, Fisher HM, et al. The effects of a randomized trial of brief forms of stress management on RAGE associated S100a8/a9 in patients with breast cancer undergoing primary treatment. Cancer. 2019; 125: 1717–1725.

Díaz A, Taub CJ, Lippman ME, Antoni MH, Blomberg BB. Effects of brief stress management interventions on distress and leukocyte nuclear factor kappa B expression during primary treatment for breast cancer: a randomized trial. Psychoneuroendocrinology. 2021; 126: 105163.

American Cancer Society. Learn about breast cancer. 2006. Available at: http://www.cancer.org/cancer/breastcancer/ (Accessed: 1 January 2022).

National Cancer Institute. Breast Cancer. 2006. Available at: https://www.cancer.gov/types/breast (Accessed: 1 January 2022).

University of Miami Health. Cancer Support Services. 2022. Available at: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center/cancer-support-services (Accessed: 1 January 2022).

Center for Disease Control. About Adult BMI. 2022. Available at: https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html (Accessed: 1 January 2022).

Antoni MH, Lechner SC, Kazi A, Wimberly SR, Sifre T, Urcuyo KR, et al. How stress management improves quality of life after treatment for breast cancer. Journal of Clinical Psychology. 2006; 74: 1143–1152.

Blair SN, Haskell WL, Ho P, Paffenbarger RS, Vranizan KM,
Farquhar JW, et al. Assessment of Habitual Physical Activity by a Seven-Day Recall in a Community Survey and Controlled Experiments. American Journal of Epidemiology. 1985; 122: 794–804.

[55] Stagl JM, Antoni MH, Lechner SC, Carver CS, Lewis JE. Post-surgical physical activity and fatigue-related daily interference in women with non-metastatic breast cancer. Psychology & Health. 2014; 29: 177–198.

[56] Ottenbacher AJ, Day RS, Taylor WC, Sharma SV, Sloane R, Snyder DC, et al. Long-term physical activity outcomes of home-based lifestyle interventions among breast and prostate cancer survivors. Supportive Care in Cancer. 2012; 20: 2483–2489.

[57] O’Connor M, Bower JE, Cho HJ, Creswell JD, Dimitrov S, Hamby ME, et al. To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers. Brain, Behavior, and Immunology. 2009; 23: 887–897.

[58] Bouchard LC, Antoni MH, Blomberg BB, Stagl JM, Gudenauf LM, Jutagir DR, et al. Post-surgical Depressive Symptoms and Pro-inflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. Psychosomatic Medicine. 2016; 78: 26–37.

[59] Blomberg BB, Alvarez JP, Diaz A, Romero MG, Lechner SC, Carver CS, et al. Psychosocial adaptation and cellular immunity in breast cancer patients in the weeks after surgery: an exploratory study. Journal of Psychosomatic Research. 2009; 67: 369–376.

[60] IBM SPSS Statistics for Windows. Version 27.0. IBM Corp.

[61] Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhausser ML, Wener MH, et al. Elevated Biomarkers of Inflammation are Associated with Reduced Survival among Breast Cancer Patients. Journal of Clinical Oncology. 2009; 27: 3437–3444.

[62] Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. International Journal of Cancer. 2003; 103: 642–646.

[63] Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Dae A, Blay J. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. British Journal of Cancer. 2003; 88: 1721–1726.

[64] Knüpfel H, Preiß R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Research and Treatment. 2007; 102: 129–135.

[65] Hamer M, Sabia S, Batty GD, Shipley MJ, Tabák AG, Singh-Manoux A, et al. Physical Activity and Inflammatory Markers over 10 Years. Circulation. 2012; 126: 928–933.

[66] St. Fleur RG, St. George SM, Antoni MH. Cognitive Behavioral Stress Management and Physical Activity Outcomes in Breast Cancer Survivors: A Two-Part Latent Growth Model. Oral paper presentation at the 43rd Annual Meeting of the Society of Behavioral Medicine. Baltimore, MD, 2022.

[67] Tomiyama AJ, Carr D, Granberg EM, Major B, Robinson E, Sutin AR, et al. How and why weight stigma drives the obesity ‘epidemic’ and harms health. BMC Medicine. 2018; 16: 123.

[68] Puhl RM, Andreyeva T, Brownell KD. Perceptions of weight discrimination: prevalence and comparison to race and gender discrimination in America. International Journal of Obesity. 2008; 32: 992–1000.

[69] Phelan SM, Dovidio JF, Puhl RM, Burgess DJ, Nelson DB, Yeazel MW, et al. Implicit and explicit weight bias in a national sample of 4,732 medical students: the medical student CHANGES study. Obesity. 2014; 22: 1201–1208.

[70] Meadows A, Higgs S. Internalised Weight Stigma Moderates the Impact of a Stigmatising Prime on Eating in the Absence of Hunger in Higher- but Not Lower-Weight Individuals. Frontiers in Psychology. 2019; 10: 1022.

[71] Haedt-Martt AA, Keel PK, Racine SE, Burt SA, Hu JY, Boker S, et al. Do emotional eating urges regulate affect? Concurrent and prospective associations and implications for risk models of binge eating. International Journal of Eating Disorders. 2014; 47: 874–877.

[72] Konttinen H, van Strien T, Männistö S, Joulislati P, Haukkala A. Depression, emotional eating and long-term weight changes: a population-based prospective study. International Journal of Behavioral Nutrition and Physical Activity. 2019; 16: 28.

[73] Roosen MA, Safer D, Adler S, Cebolla A, van Strien T. Group dialectical behavior therapy adapted for obese emotional eaters: a pilot study. Nutrition Hospitalaria. 2012; 27: 1141–1147.

[74] Katterman SN, Kleinman BM, Hood MM, Nackers LM, Corsica JA. Mindfulness meditation as an intervention for binge eating, emotional eating, and weight loss: a systematic review. Eating Behaviors. 2014; 15: 197–204.

[75] Ogden J, Coop N, Cousins C, Crump R, Field L, Hughes S, et al. Distraction, the desire to eat and food intake. towards an expanded model of mindless eating. Appetite. 2013; 62: 119–126.

[76] Warren JM, Smith N, Ashwell M. A structured literature review on the role of mindfulness, mindful eating and intuitive eating in changing eating behaviours: effectiveness and associated potential mechanisms. Nutrition Research Reviews. 2017; 30: 272–283.

[77] Polivy J. Psychological Consequences of Food Restriction. Journal of the American Dietetic Association. 1996; 96: 589–594.

[78] Mattila E, Lappalainen R, Pärkkä J, Salminen J, Korhonen I. Use of a mobile phone diary for observing weight management and related behaviours. Journal of Telemedicine and Telecare. 2010; 16: 260–264.

[79] Pronk NP, Crain AL, VanWormer JJ, Martinson BC, Boucher JL, Cosentino DL. The Use of Telehealth Technology in Assessing the Accuracy of Self-Reported Weight and the Impact of a Daily Immediate-Feedback Intervention among Obese Employees. International Journal of Telemedicine and Applications. 2011; 2011: 909248.

[80] Di Zazzo E, Polito R, Bartollino S, Nigro E, Porcile C, Bianco A, et al. Adiponectin as link factor between adipose tissue and cancer. International Journal of Molecular Sciences. 2019; 20: 839.

[81] Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipocytokines-induced chronic inflammation. Journal of Cancer. 2016; 7: 2346–2359.

[82] Tumminia A, Vinciguerra F, Parisi M, Graziano M, Sciacca L, Baratta R, et al. Adipose tissue, obesity and adiponectin: role in endocrine cancer risk. International Journal of Molecular Sciences. 2019; 20: 2863.

[83] Yu Z, Tang S, Ma H, Duan H, Zeng Y. Association of serum adiponectin with breast cancer: A meta-analysis of 27 case-control studies. Medicine. 2019; 98: e14359.

[84] Tsutsumi S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of c-erbB2 expression in breast cancer. Journal of Surgical Oncology. 2002; 79: 216–223.

[85] Picon-Ruiz M, Morata-Tafira C, Valle-Gofin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA: A Cancer Journal for Clinicians. 2017; 67: 378–397.

[86] Jiralepsong S, Goodwin PJ. Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. Journal of Clinical Oncology. 2016; 34: 4203–4216.